针对COVID-19的冠状病毒蛋白基亚单元疫苗的临床前安全性和免疫性研究

Kamshat Shorayeva1, Aziz Nakhanov1, Ainur Nurpeisova1

  • 1Research Institute for Biological Safety Problems, The Ministry of Health of the Republic of Kazakhstan, Gvardeiskiy 080409, Kazakhstan.

Vaccines
|December 23, 2023
PubMed
概括

该QazCoVac-PCOVID-19亚单元疫苗证明了安全性,并在动物模型中诱导了显著的抗体反应. 根据这些有希望的临床前发现,建议对SARS-CoV-2预防进行进一步的临床试验.